

Prostate Cancer (Adenocarcinoma) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: I IIA IIB III IV Recurrent

Line of Treatment: Neoadjuvant/Pre-Op Adjuvant/Post-Op First Line Second Line Third Line Third Line+

ECOG Performance Status: 0 1 2 3 4

Biomarkers:

Castration-resistant: Yes No

Prostate Cancer Recurrence Risk: Very Low Low Intermediate High Very High

Adjuvant Therapy | Post-prostatectomy | Lymph node positive (LN+)

Goserelin (Zoladex) 3.6 mg monthly or 10.8 mg q 3 mos. ¹⁻²

Leuprolide (Eligard/Lupron) 7.5mg q mos. or 22.5 mg q 3 mos. or 30mg q 4 mos. or 45mg q 6 mos. ¹⁻²

Triptorelin (Trelstar) 3.75 mg q mos. or 11.25 mg q 3 mos. or 22.5 q 6 mos. ¹⁻²

Intermediate risk | Primary treatment with radiation therapy (RT)

Goserelin* (Zoladex)* 3.6 mg monthly or 10.8 mg q 3 mos. ^{3,5}

Leuprolide (Eligard/Lupron)* 7.5mg q mos. or 22.5 mg q 3 mos. or 30mg q 4 mos. or 45mg q 6 mos. ^{3,5}

Triptorelin (Trelstar)* 3.75 mg q mos. or 11.25 mg q 3 mos. or 22.5 q 6 mos. ^{3,5}

High Risk (T3a or Gleason 8-10), Very High Risk (T3b-T4), and Locally Advanced Prostate Cancer (LN+) | Primary treatment with radiation therapy (RT)

Goserelin (Zoladex)* ⁴

Histrelin (Vantas)* ⁴

Leuprolide (Eligard/Lupron)* ⁴

Triptorelin (Trelstar)* ⁴

Recurrent and Metastatic disease | Hormone Sensitive

Docetaxel (Taxotere)** (q 3 wks) with Androgen Deprivation Therapy (ADT) ¹⁸

Goserelin (Zoladex)** ⁶

Histrelin (Vantas)** ⁶

Leuprolide (Eligard/Lupron) ** ⁶

Triptorelin (Trelstar)** ⁶

*May be coadministered with bicalutamide (Casodex) or flutamide (Eulexin) for up to 30 days in patients who are at risk of developing symptoms associated with testosterone flare.

**ADT: histrelin (Vantas), goserelin (Zoladex), leuprolide (Eligard/Lupron), triptorelin (Trelstar)



Prostate Cancer (Adenocarcinoma) Pathways (continued)

Recurrent and Metastatic Disease | Hormone Resistant | First and subsequent lines of therapy (1st Line+)

Abiraterone (Zytiga)** with continue ADT ^{8,12}

Degarelix (Firmagon) with bicalutamide (Casodex)⁷

Docetaxel (Taxotere)** (q3 wks) with continue ADT ^{10,18}

Goserelin (Zoladex) with bicalutamide (Casodex) ^{6,7}

Leuprolide (Eligard/Lupron) with bicalutamide (Casodex) ^{6,7}

Triptorelin (Trelstar) with bicalutamide (Casodex) ^{6,7}

Recurrent and Metastatic Disease | Hormone Resistant | Second and subsequent lines of therapy (2nd Line +)

Cabazitaxel (Jevtana)** with ADT ¹¹

Docetaxel (Taxotere)** rechallenge with ADT ²⁰⁻²¹

Enzalutamide (Xtandi)** with ADT ¹⁵

Continued ADT ** with supportive care ± dexamethasone ^{13-14,22-24}

*May be coadministered with bicalutamide (Casodex) or flutamide (Eulexin) for up to 30 days in patients who are at risk of developing symptoms associated with testosterone flare.

**ADT: histrelin (Vantas), goserelin (Zoladex), leuprolide (Eligard/Lupron), triptorelin (Trelstar)

